Opens in a new tab

Breaking news

OpenAI Unveils Enhanced Image Generator API for Developers

In a significant leap for AI capabilities, OpenAI has opened up its improved image generation technology to developers through its API. This move signifies a bold step forward in integrating AI-generated visuals into diverse applications and services.

Launched initially in ChatGPT, the new image generator gained rapid popularity due to its ability to create realistic, Studio Ghibli-style illustrations and imaginative AI action figures. Its widespread use led to an exceptional surge in ChatGPT sign-ups, with over 130 million users producing a staggering 700 million images in just one week.

The technology behind this innovation, known as ‘gpt-image-1’, is a versatile multimodal model capable of crafting images across various styles, guided by custom parameters, and embedding text with precision. Developers leveraging this API can generate multiple images simultaneously while adjusting the quality and speed of image production.

OpenAI ensures that its image generation adheres to robust safety protocols, employing guardrails to prevent non-compliant content creation. Developers have the choice to customize content moderation, balancing between standard and low-filter options, the latter allowing a broader range of content categories.

Moreover, all AI-generated images carry C2PA metadata, allowing supported platforms to identify them as AI-created, integral in maintaining authenticity and transparency.

Cost-effectiveness remains crucial, with pricing set at $5 per million input tokens for text and $10 per million input tokens for images, scaling to $40 per million output tokens. This equates to approximately 2-19 cents per generated image, depending on quality.

Many notable companies, including Adobe and Canva, are experimenting with integrating this groundbreaking technology. Platforms like Figma have even added features that empower users to edit and create images directly through GPT-Image-1.

As AI technology continually evolves, this development not only marks a milestone for OpenAI but also underscores the potential of AI in enhancing creativity and efficiency across various industries. For a deeper dive, discover how Cyprus’s tech ventures are also leaping forward.

Cyprus Joins European Genome Project To Advance Personalised Medicine

Genetic information could help doctors identify which treatments are most likely to work for individual patients, predict potential side effects and uncover inherited causes of diseases that are difficult to diagnose. Cyprus is contributing to a major European initiative aimed at making this approach more effective by expanding the understanding of genetic diversity across the continent.

The Genome of Europe programme brings together 49 partners from 27 countries to establish a shared reference database containing at least 100,000 human genomes. With a budget of €45 million, including €20 million from the European Commission’s Digital Europe programme, the initiative began in autumn 2024 and is scheduled to run for three and a half years.

Cyprus is participating through biobank.cy, the Centre of Excellence for Biobanking and Biomedical Research at the University of Cyprus. Its contribution includes sequencing the complete genomes of at least 310 Cypriot volunteers.

Why Europe Needs A More Diverse Genetic Reference

Although most human DNA is shared, small genetic differences can influence inherited conditions, disease susceptibility and how individuals respond to medicines.

These variations differ between populations. A reference database based primarily on a limited range of genetic backgrounds may therefore provide less accurate insights for groups that are underrepresented. Genome of Europe aims to address this gap by building a dataset that better reflects the continent’s genetic diversity.

“Populations, such as that of Cyprus, have their own specific characteristics,” said Katerina Strati, an associate professor in the University of Cyprus’s Department of Biological Sciences. She explained that findings from other populations cannot automatically be applied to Cypriots.

A population-specific reference genome gives researchers a baseline against which to assess genetic variants, helping them determine whether a particular variation is common or rare among people with a similar background. This can improve the interpretation of genetic tests and research into disease risks.

Mapping The Genetic Profile Of Cyprus

Efforts to map the genetic profile of the Cypriot population began in 2019. Through the Cypriot Human Genome Project, known as CYPROME, researchers have already analysed more than 1,000 exomes from local volunteers. Unlike whole-genome sequencing, which examines a much broader portion of DNA, exome sequencing focuses on the protein-coding regions of genes.

Apostolos Malatras, a senior bioinformatician at biobank.cy, said population-specific genetic data could help researchers interpret individual findings more accurately and eventually support better-informed treatment decisions.

The centre’s research infrastructure includes more than 123,000 biological samples, 12,257 volunteers and participation in 14 research programmes. These figures represent different measures: one volunteer may provide multiple samples, and sample collection does not necessarily mean that a genome has been sequenced.

Its research covers hereditary kidney diseases, heart conditions and other illnesses, including work on preclinical models for rare kidney diseases such as Alport syndrome.

Malatras said a better understanding of genetic differences could eventually help develop more personalised medicines and improve treatment selection.

Mariel Voutounou, a project manager at the centre, compared the development of new treatments to a long-distance race. Building the necessary collection of biological samples and research data takes time, she said, but an established biobank gives scientists a valuable starting point.

Protecting Genetic Data And Volunteer Rights

Because genetic information can reveal details about a person’s health and potentially affect their biological relatives, data protection and informed consent are central to the project.

biobank.cy operates with approval from the National Bioethics Committee of Cyprus and complies with the EU’s General Data Protection Regulation. Its safeguards include technical and organisational measures to restrict access to personal information.

Georgia Charalambidou, who leads the centre’s work on ethical, legal and social issues and education, said volunteers receive information about the research, have time to consider participation and can ask questions before signing a consent form.

Participation is voluntary, and individuals can withdraw their consent at any time without affecting their medical treatment or relationship with their doctor.

The centre has also surveyed approximately 569 people in Cyprus to understand public attitudes towards genetic testing and research participation. According to Charalambidou, the findings indicated broad support for genetic research, alongside clear expectations about transparency and how personal data are used.

The results also suggested that people with experience of patients diagnosed with a particular condition were more likely to favour receiving genetic findings through specialist doctors. This highlights the importance of explaining both the potential benefits and the limitations of genetic testing.

Sharing Research Without Transferring Sensitive Data

International cooperation presents another challenge: enabling researchers to compare genetic information across countries while protecting sensitive personal data.

The European Genomic Data Infrastructure is designed to connect national systems securely. Rather than transferring underlying files between countries, researchers can conduct analyses within the systems where the data are stored, Malatras explained.

This approach is particularly relevant to rare diseases, where individual countries may have relatively few diagnosed cases. Comparing data across populations can help researchers identify genetic patterns that might otherwise remain difficult to detect.

From Genetic Research To More Personalised Treatment

Precision medicine is already used in some areas of healthcare, particularly oncology, where genetic information can help guide treatment decisions. However, developing medicines tailored to each patient’s genetic profile remains a longer-term ambition.

Genome of Europe aims to strengthen the evidence base needed to advance this approach. Its success will depend not only on the number of genomes collected but also on how accurately researchers interpret the data, represent different populations and translate findings into safe clinical applications.

For Cyprus, contributing genetic data from its population will help ensure that local genetic characteristics are represented in European research. In the longer term, this could support earlier diagnoses, more informed prevention strategies and treatments better suited to individual patients.

Uol
Aretilaw firm
The Future Forbes Realty Global Properties
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter